Videos

At the 2022 San Antonio Breast Cancer Symposium, Mafalda Oliviera, MD, PhD, discusses results from the SERENA-2 trial, investigating camizestrant for ER-positive, HER-2 negative, metastatic breast cancer that had progressed on endocrine...

Seth Wander MD, PhD, discusses research presented at the 2022 San Antonio Breast Cancer Symposium, focusing on the genomic and molecular mechanisms of resistance to CDK4/6 inhibitors and antiestrogens in metastatic breast cancer.

Jan Burger, MD, PhD; Nitin Jain, MD; and Alessandra Ferrajoli, MD, discuss 4-year follow-up data from a phase 2 trial exploring combined ibrutinib and venetoclax for the first-line treatment of patients with CLL.

Martin Dreyling, MD, discusses data from the Triangle trial showing strong efficacy and acceptable safety with the addition of ibrutinib to induction or maintenance treatment with or without autoHSCT in younger patients with MCL.

At the 2022 San Antonio Breast Cancer Symposium, Matthew Goetz, MD, discusses a translational end point from the ELAINE-1 trial, examining patient outcomes for HR-positive, HER2-negative breast cancer with an ESR1 mutation treated with...

Erika Hamilton reviews updated results from a trial investigating trastuzumab deruxtecan alone and in different combinations, notably with pertuzumab, in the first-line setting for patients with metastatic HER2-positive breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Joseph Sparano, MD, discusses the efficacy of endocrine therapy alone for patients with ER-positive, HER2-negative, lymph node-negative breast cancer.

At the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, Gary Deng, MD, discusses modes of complementary medicine that patients with gastrointestinal cancers may be curious about.

Srdan Verstovsek, MD, presents data on real-world outcomes of the use of ruxolitinib in patients with myelofibrosis who had anemia or thrombocytopenia at the ASH 2022 Meeting in New Orleans, LA.

Srikala Sridhar, MD, shares insights from a study investigating how metastatic hormone sensitive prostate cancer care has changed during the COVID-19 pandemic.